Myriad Genetics, Inc.
MYGN
$3.84
-$0.27-6.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -6.98% | -1.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -6.98% | -1.27% | |||
| Cost of Revenue | 3.35% | -5.98% | |||
| Gross Profit | -11.07% | 0.73% | |||
| SG&A Expenses | -0.22% | -2.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.32% | -1.38% | |||
| Operating Income | -67.63% | 2.81% | |||
| Income Before Tax | 24.81% | -84.43% | |||
| Income Tax Expenses | -961.76% | 277.78% | |||
| Earnings from Continuing Operations | 99.76% | -92.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 99.76% | -92.31% | |||
| EBIT | -67.63% | 2.81% | |||
| EBITDA | -484.00% | -13.64% | |||
| EPS Basic | 99.76% | -91.90% | |||
| Normalized Basic EPS | -92.71% | 20.14% | |||
| EPS Diluted | 99.77% | -92.72% | |||
| Normalized Diluted EPS | -92.71% | 20.14% | |||
| Average Basic Shares Outstanding | 0.33% | 0.22% | |||
| Average Diluted Shares Outstanding | 0.33% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||